Using recombinant DNA technology, we have generated Chinese hamster ovary (CHO) cell lines that synthesize latent transforming growth factor Nt (TGF-/3t) to study immune regulation by TGF-Rt. In vitro, latent TGF-(3t synthesized by transfectants or added exogenously as a purified complex after activation inhibited CTL generation to a similar extent as seen with acid-activated recombinant human (rHu) TGF-tit. In vivo, serum from nulnu mice bearing CHO/TGF-R1 tumors contained significant levels of latent TGF-al in addition to depressed natural killer (NK) activity in spleens which paralleled that seen in C3H/HeJ mice treated with acid-activated rHuTGF-tit . rHuTGF-#l treatment of mice receiving heart allografts resulted in significant enhancement of organ graft survival. Because of possible regulated tissue-specific activation, administration oflatent rather than active TGF-0 may provide a better route to deliver this powerful immunosuppressive agent in vivo.
T ransforming growth factors encompass a family ofpolypeptides that regulate the growth and differentiation of both normal and transformed cells (1, 2) . One of these, TGF-a1, has been isolated and purified from various normal and neoplastic cells. Molecular cloning and sequencing ofthe cDNA for TGF-/mot (3) in conjunction with protein structural data (4) (5) (6) showed that TGF-f+1 is synthesized as a precursor protein of 391 amino acid residues and subsequently processed after signal peptidase and proteolytic cleavage to a 112 residue (Mr 12,500) form. The active or "mature" TGF-#t homodimer (25 kD) is noncovalently associated with the remainder of its precursor form (75-kD dimer), and in platelets covalently linked with one molecule of TGF-R1 binding protein (135 kD) (5, 7, 8) or in serum associated with a2-macroglobulin (9) to form a high molecular weight inactive "latent" complex unable to bind TGF-0 cellular receptors (10) . TGF-,81 can be activated by exposure to extremes ofpH, heat, or by treatment with chaotropic agents, proteases, ;or glycosidases (11) (12) (13) (14) . However, the physiological processes by which latent TGF-01 is activated have not yet been fully elucidated.
Numerous studies have described the pleiotropic nature of the biologically active form of TGF-a1. In addition to its potent effects on cell proliferation and differentiation, TGF-/31 plays an active role in wound healing, tissue repair, and regulation ofimmune responses (1, 15, 16) . The immunoregulatory properties of TGF-01 include inhibition of thymocyte proliferation (17-19), T and B cell proliferation, production of IgM or IgG (20-22), but not IgA synthesis which TGF-a enhances (23, 24), cytokine production (25), NK cell activity (26), cytotoxic T cell development (27) (28) (29) , and lymphokineactivated killer (LAK) 1 cell activity (28, 30) . With regard to monocytes/macrophages, TGF-0 displays both inhibitory and stimulatory effects . TGF-0 can induce monocyte chemotaxis, and enhance mRNA expression for TNF-ci and IL1 (31, 32) while deactivating macrophages by reducing their capacity to release H202, cytotoxicity activity, class II and Fc,R2 expression, as well as TNF-ci and 11,1 production, thus perhaps imposing negative feedback and limiting the detrimental effects of toxic monokines (33) (34) (35) (36) .
Many of the studies that establish TGF-0 as a regulator of immune function have examined the immunoregulatory effects ofacid-activated TGF-0 in vitro. However, the potential clinical usefulness of TGF-0 as an immunosuppressant relies also on in vivo studies, few ofwhich have been reported . Second, physiological TGF-# is first presented in vivo as a latent complex incapable of binding TGF-0 receptors (10) and regulating immune functions. It is not clear from previous studies using activated TGF-0 that latent or endogenous TGF-0 can be activated both in vitro and in vivo to regulate immune responses. To address these questions, we investigate the immunoregulatory properties of TGF-0 using latent recombinant human TGF-{$1 (rHuTGF-Oi) produced in Chinese hamster ovary (CHO) cells and compare the immune activities of latent and acid-activated rHuTGF-at . We conclude that mechanisms exist in vitro and in vivo to activate latent TGF-0 which in an autocrine or paracrine manner can suppress immune function . The possible role of active TGF-0 in immune surveillance is discussed.
Materials and Methods
Cell Culture and cDNA Transfection. Chinese hamster ovary (CHO) cells deficient in dihydrofolate reductase (dhfr) activity (37) were grown in DME/F12 (50:50) medium (Gibco Laboratories, Grand Island, NY) supplemented with 1 g/liter glucose, 10% FCS (HyClone, Logan, UT), 2 MM L-glutamine, penicillin (100 U/ml), and streptomycin (100 Wg/ml) (Gibco) and 0.133 mM glycine, 0.11 mM hypoxanthine, 0.02 mM thymidine (GHT). CHO dhfr -cells (2 x 106) were cotransfected with 1 wg of the expression vector p(SBO) containing the TGF-S, cDNA (3) driven from the cytomegalovirus immediate early promoter in pRK5 (kindly provided by R. Klein and D.V. Goeddel, Genentech, Inc.) and 100 ng of pFD11 which encodes the dhfr gene. Cells stably expressing the dhfr gene were selected in DME/F12 lacking GHT and 10% dialyzed FCS. Individual transfectant clones were selected, expanded in culture, and screened for TGF-S, production by either RIA (6) or bioassay (described below). Confirmation of rHuTGF-a, production was also determined by SDS-PAGE (6) . The integrated plasmid copy number was amplified by culturing cells in the presence of up to 1-2 F.M methotrexate in selective medium . For some experiments we used active rHdIGF-a, produced by CHO transfectant cells, purified to 0.8 mg/ml (1 pg endotoxin/lAg protein) and acid-activated by dialysis against 20 mM sodium acetate, pH 4.0 . Latent rHuTGF-S, in CHO transfectant-conditioned medium was purified by sequential cation exchange and hydrophobic chromatography (12) . The latency of purified rHuTGF-I8, was confirmed both before and after its isolation by inactivity in bioassay or TGF-0 receptor binding studies. The structure of purified latent rHuTGF-S, is representative of the small latent TGF-0 complex composed of the active 25-kD TGF-IQ dieter noncovalently associated with the 75-kD precursor remnant, but lacking the 135-kD binding protein found in the platelet large latent complex (6) . For ease in reading the text the following abbreviations are used; CHO for parental CHO dhfr -cells, CHO dhfr' and CHO/ TGF-0, refer to CHO dhfr -mutant cell line that has been transfected and expresses dhfr, dhfr and rHuTGF-I#, activities, respectively.
TG-/3 Bioassay. A subclone of the Mv1Lu mink lung cell line (American Type Culture Collection, Rockville, MD) isolated in our laboratory was used to measure TGF-0 activity (38) . Conditioned medium or serum were assayed either untreated or after treatment with 0.12 N HCl for 15 min at room temperature followed by neutralization with O.1M HEPES buffer containing 0.144 M NaOH (acid-activated) . Samples diluted in MEM supplemented with 2 MM L-glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 100 U/ml penicillin, 100 ttg/ml streptomycin (complete MEM [CMEM] ) (all reagents from Gibco Laboratories) 1778 and 0.1% FCS (HyClone) were added to cultures in 96-well flatbottomed microtiter plates (Costar, Cambridge, MA). The plates were incubated at 37°C with 5% COa for 24 h and pulsed during the last 4 h with 1 ttCi of ['H]thymidine in CMEM (6 .7 Ci/ mmol ; Amersham Corp., Arlington Heights, IL). Cells were harvested using a PHD Cell Harvester (Cambridge Technology, Inc., Watertown, MA) and ['H]TdR incorporation was measured with a liquid scintillation counter. Results (picograms/milliliter of TGF-S) were calculated based on percent decrease in [3H]TdR incorporation compared with a rHuTGF-P, standard . The lower detection limit of the bioassay was 10 pg/ml TGF-0. Samples containing rHuTGF-S that show negligible bioactivity without acid-activation are considered "latent," i.e ., biologically inactive.
Animals . 6-8-wk-old BALB/c nu/nu female mice and C57BL/6 (B6) female mice were purchased from Charles River Breeding Laboratories, Wilmington, MA, C3H/HeJ female mice were obtained from Jackson Laboratories, Bar Harbor, ME . For the transplantation studies adult (8-10 wk) male C3H/km mice and neonatal (24-48 h) unsexed BALB/c mice were obtained from the Department of Radiobiology, Stanford University Medical Center, Stanford, CA .
Animals Studies. BALB/c nu/nu mice were injected subcutaneously with 10' CHO or CHO/TGF-S transfected cells (>95% viable as judged by Trypan blue exclusion) washed with PBS (0.15 M NaCl, pH 7.0) and tumor size determined based on the average of the two cross-sectional diameters of each tumor. Serum samples were withdrawn for quantitation of TGF-a, by bioassay and spleens were assayed for NK activity. C3H/HeJ mice were injected by various routes with various doses of acid-activated rHuTGF-/3, and spleen cells were assayed for NK activity.
For NK assays, spleen effector cells harvested from nu/nu or C3H/HeJ mice were washed three times in CMEM and seeded at various concentrations into 96-well round-bottomed tissue culture plates (Costar) in CMEM supplemented with 10% FCS. YAC-1 target cells were labeled with 150 p.Ci of Na"Cr04 (5 mCi/ml ; Amersham Corp.) for 45 min at 37°C and after three washes with CMEM, 104 target cells were added to effector cells at various concentrations in 96-well round-bottomed microtiter plates (Costar) . After 4 h of incubation at 37°C, culture supernatants were harvested (Skatron, Sterling, VA) and radioactivity was quantitated using an automatic gammacounter (Micromedic Systems, Hersham, PA). Percent specific lysis was calculated as 100 x [[cpm of combined effector and target cells supernatants (experimental release) -cpm of supernatants of target alone (spontaneous release)]/[cpm after lysis of targets with 2% NP-40 (maximum release) -spontaneous release]). Results are expressed as mean of triplicate determinations ± SEM. Spontaneous release of target cells alone was <10% of maximum for all experiments.
Cytotoxic T Lymphocyte Generation. CTLs were generated in 5-d cultures by incubation in T25 culture flasks of 2.5 x 10' B6 responding spleen cells and 2.5 x 106 stimulator CHO or CHO/ TGF-S, transfectant cells (irradiated 5,000 rad) in 10 m1 of CMEM + 10% FCS. It should be noted that CHO/TGF-S, cells used in the one-way MLC still accumulate TGF-0, into culture medium after 5,000-rad irradiation. For some experiments B6-anti-CHO CTLs were generated in the presence of various concentrations of acid-activated rHuTGF-0,, purified latent rHtfGF-0,, or acidactivated purified latent rHuTGF-S,. After 5 d of culture effector cells were assayed for cytolytic activity against various "Cr-labeled, CHO cell lines that were labeled with "Cr as indicated for YAC-1 cells, and cytotoxicity assays were performed as described (27) .
Mouse Heterotopic Cardiac Transplantation Model. A mouse pinna (ear)-heart transplant model was used in which a newborn BALB/c
Comparison of Active and Latent Transforming Growth Factor a, donor heart is transplanted into a surgically constructed subdermal pocket on the left dorsal pinna of an adult C3H/km recipient . Recipient mice were anesthetized via intraperitoneal injection ofchloral hydrate dissolved in saline (25 mg/kg) and a2-mm epidermal/dermal incision was made parallel to the body axis and 2-3 mm distal to the ear-skull junction . An oval subcutaneous pouch measuring 3-4 mm in diameter was formed on the ear by inserting one arm of a small curved forceps into the incision separating the epidermal/dermal layer from the underlying cartilage. The donor heart was extracted en bloc via thoracotomy and both atria were removed. Excess air and fluid were expressed from the pouch with a cotton swab to facilitate maximal contact between donor and recipient tissues .
Treatment groups received intraperitoneal injection ofeither activated rHuTGF-#, at various doses or normal saline scheduled at various intervals for 13 d after surgery. On the sixth postoperative day and on every other day thereafter until graft failure, the grafts were visually examined for contractions by using a stereomicroscope (Stereozoom No. 4; Bausch and Lomb Co., Rochester, NY) at 10-2-fold magnification . Graft viability was evaluated in a binary fashion (+ or -) based upon the presence or absence ofgraft contractions. All animals were weighed periodically to monitor drug toxicity.
Results
Production ofLatent 7GRa1 by CHO Transfectants. Our initial studies used CHO cells lines 12/20/6 and 61-1/7C3C12A engineered to produce recombinant TGF-flt (CHO/TGF-/31). To demonstrate that the TGF-01 secreted from the CHO/TGF-01 transfectants was latent, conditioned medium from CHO/TGF-Ot cells was analyzed for bioactivity with or without acid-treatment . The data indicate that clones 12/20/6 and 61-1/7C3C12A produced significant quantities of recombinant latent TGF-fl, after 2 d of in vitro culture ofwhich >90-98% was detectable by bioassay only after acid-activation (Table 1) ; the rHuTGF -Iat secreted by the higher producing clone 12/20/6 was also incapable of binding TGF-0 cellular receptors as determined by radioreceptor assay (Dr. Lalage Wakefield, personal communication) . Media obtained from parental CHO cells showed background levels ofTGF-f. SDS-PAGE analysis showed that the rHuTGF-01 synthesized by CHO transfectants formed a high molecular weight complex with molecular species of Mr 100,000 and 75,000, consistent with the presence of processed precursor and precursor remnant, respectively, similar in structure to platelet latent complex but lacking the 135-kD binding protein (data not shown, reference 6).
rHuTGF-01 Inhibits CTL Generation In Vitm We have shown previously that activated rHuTGF-fl, can inhibit the generation of CTL in vitro but not their cytolytic activity (27) . The studies presented now further examined whether (a) latent TGF-,f3-secreting CHO cell lines can inhibit CTL generation in vitro and (b) such CHO cells can serve as targets for B6 anti-CHO-specific CTL . The data in Fig. 1 indicate that 136 spleen cells generated potent CTL against the CHO parental and CHO dhfr+ cells but not CHO/TGF-01 stimulator cells. In contrast, B6 anti CHO-specific CTL exhibited similar cytolytic activity against the CHO parental cells, CHO dhfr+ cells and CHO/TGF-/31 cells in 4-h CTL
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Wallick et al. Figure 2 . Effect of latent TGF-0, on CTL generation . B6-anti-CHO CTLs were generated in the presence of 10 ng/ml acid-activated (E)), latent (O) and acid-activated (A) rHuTGF-01, or non-TGF-01-containing buffer ("), and were tested in a 4-h cytotoxicity assay against s1 Cr-labeled CHO target cells as described in Materials and Methods. Data shown are the mean of triplicate values t SEM performed at an E/T ratio of 25 :1 . Similar results were obtained at all other E/T ratios tested (data not shown) .
exist in vitro to convert latent TGF-0 into a biologically active form that can regulate antitumor responses .
We next investigated whether latent/activatable rHuTGF-/3 1 was as effective in suppressing CTL generation in vitro as acid-activated rHuTGF-01 . Both untreated and acid-activated latent rHuTGF-101 inhibited CTL generation that was dosedependent and in a manner similar to that of activated rHuTGF-01 (Fig. 2) . The concentration necessary to inhibit to 50% (ID5o) the maximal CTL response was 0.63, 0.73 and 0.83 ng/ml acid-activated, latent/acid-activated, and latent rHuTGF-gi, respectively, for the experiment shown (Fig. 2) . These data suggest that latent TGF-0 is effectively converted to its active form in a manner quantitatively similar to activation by acid pH. Although the latent preparation contained ti5% active fraction (as determined by radioreceptor assay), the [ID5o] for latent, latent/activated, and activated rHuTGF-S, suggest that the inhibitory activity is not the result of pre-existing activated TGF-0 but rather the conversion of latent rHuTGF-01 to active polypeptide.
Tumor Growth and TGRO Production In Viva Tumor growth was observed in nu/nu mice injected subcutaneously with 1 x 107 CHO/TGF-S, cells (Table 2 ). Over the 30-d examination period, the tumors grew progressively but were nonlethal . Tumor formation was observed in some animals as early as the first day after cell inoculation, with all animals demonstrating measurable tumors by day 5 after the study start . Elevated TGF-0, levels were observed in the CHO/ TGF-Q1 bearing nu/nu mice compared with baseline levels of untreated controls (Table 2 ). Serum levels of activatable TGF-0 increased as the study progressed, and tumors increased in size. In the two animals, which regressed the CHO tumor (one on day 14 and the other on day 30) the serum TGF-R levels were significantly lower in comparison with those obtained for the tumor bearing mice (data not shown) . These results suggest that the CHO/TGF-/3, cells lines continue to synthesize rHuTGF-/31 in vivo which circulates in a latent but potentially activatable form.
E~fect ofrHuTGRO, on Murine Lymphoid Functions. Acidactivated human platelet--derived TGF-I01 has been shown to inhibit NK activity in vitro (26). However, the effects o£ both latent and acid-activated TGF-O, on NK activity in vivo have not been reported . As shown in Fig. 3 A, the i.p. injection of 1 gg acid-activated rHuTGF-01 suppressed NK activity even after a single administration . Maximum inhibition was observed when rHuTGF-(31 was administered daily. Less sup-
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Comparison of Active and Latent Transforming Growth Factor 01 BALB/c nu/nu mice were used; injections, tumor measurements, and determinations of serum TGF-0 levels were performed as indicated in Materials and Methods Represents serum levels of activated TGF-0 ± SEM obtained after acid-activation for tumor-bearing animals. All nonacid-activated serum contains less than detectable levels of TGF-fl (detection limit 20 pg/ml) . t Average size ± SEM includes only tumor-bearing animals. Effector : Target Cell Ratio pression was obtained when 0.1 Ag rHufGF-)3 was administered (data not shown) . Administration of 2 pg of activated rHdrGF-P1 daily by either the intraperitoneal, intravenous, or subcutaneous route reduced NK activity to a similar degree (Fig. 3 B) . The i.p. administration of rHuTGF-0 1 proved consistently the most effective in suppressing NK activity. As our previous data demonstrated that predominantly latent rHuTGF-01 was produced in vivo by CHO/TGF-,81 cells we questioned whether mice bearing these CHO-TGF-(31 tumors exhibited changes in NK activity. The results demonstrated a significant reduction in NK activity in the tumor-bearing mice (Fig. 3 C) . NK activity for nulnu mice bearing CHO dhfr+ cell tumors was similar to that of untreated control animals (data not shown) . The spleen cells from mice administered 1 jig rHuTGF-01 intraperitoneally which showed reduced NK activity also demonstrated a suppressed responsiveness to Con A in comparison with untreated control animals (data not shown). However, it is interesting that in certain studies, mice treated with rHuTGF-01 demonstrated reduced NK levels without the concomitant suppression ofCon A responses (data not shown) . The findings support that latent TGF-(3 activated in vivo can suppress NK activity and the ability to respond to mitogenic stimuli. Treatment with rHuTGF-f1 Prolongs Organ Graft Survival in Heart Transplant Recipient Mice. Additional studies were performed to determine the efficacy of activated rHuTGF-01 as an immunosuppressant in organ transplantation. C3H/km recipients of BALB/c heart allografts were treated intraperitoneally with 1 ug or 5 jug activated rHuTGF-fl, on days 1-13 or 4-13 after transplant. The drug delivery schedule included the days before and after allograft vascularization, day 4, and the period ofallograft rejection, days 10-14. Allograft survival time was defined as the first day on which graft contraction, i.e., rejection, ceased. The data in Table 3 indicate that percent heart graft survival in rHuTGF-fl1-treated groups was significantly prolonged using both rHuTGF-01 doses compared with the saline treated control group. No significant difference in mean graft survival time was observed between treatment groups administered activated rHuTGF-01 on either day 1 or day 4 after transplantation (Table 3) quired higher doses of 3-6 mg/kg in this model to achieve similar graft survival (data not shown) . In addition, activated rHuTGF-/31 also suppressed the T cell-mediated increased lymph node enlargement occurring in host-versus-graft popliteal lymph node assay (data not shown) .
Discussion
We have examined the immunoregulatory effects of TGF-13 using CHO lines that synthesize and secrete latent rHuTGF-(31. Latent TGF-/3 was chosen as substrate to define the conditions under which immune cells process latent TGF-f to a functional polypeptide. The latency of rHuTGF-01 was determined by inactivity in biological growth inhibition and radioreceptor assays. While it is generally true that most cells synthesize latent TGF-0 (3), some cell lines such as the human breast cancer cell lines MCF-7 and T-47D, and human glioblastoma cells have been reported to secrete TGF-a that is biologically active without activation by acid, pH, or urea (39) (40) (41) . The different mechanisms regulating the decision whether to release TGF-a as active or latent product is currently unclear. Since only active TGF-/l can bind to cellular receptors (10), elucidation of those cells that can either acti- vate TGF-0 directly, or are in proximity to those cells that can, is important for the understanding of autocrine or-paracrine regulation by TGF-(3. However, at least for some cells, the masking of active TGF-0 by association with "latencyassociated peptide" (LAP) appears an important means to protect themselves from the potent regulatory effects of TGF-0 they synthesize (1, 8, (20) (21) (22) 42) . In keeping with the protective role of LAP, we found that CHO/TGF-R1 cells injected into nu/nu mice secrete rHuTGF-N1 into the animal's circulation as latent protein.
Since activated TGF -R1 was not found systemically at detectable levels in CHO/TGF-R1 recipient nu/nu mice, but is required to decrease NK activity, the results suggest that TGF-01 activation is a localized event in vivo, safeguarding the release of large amounts of this growth regulator. The localized activation of latent TGF-0 may provide a means for cells to regulate TGF-0 activity only in specific tissues.
In addition to being sensitive to the inhibitory effects of TGF-R1, most lymphoid cells produce latent TGF-0 . The presumed conversion of latent or endogenous rHuTGF-01 to an active form that can inhibit immune functions was shown to occur both in vitro and in vivo. Kehrl et al. have recently reported that polyclonal antibodies to active TGF-0 can enhance B-cell proliferation and Ig synthesis (22). In addition, Lucas and co-workers have shown that mAbs to active TGF-0 can enhance the proliferation ofPBMC to IIr2 and PHA/PMA as well as the generation oflymphokine-activated killer cells . These findings suggest that endogenously produced latent TGF-0 can be activated by normal physiological mechanisms which can then downregulate in an autocrine fashion these immune functions (43) . The studies presented here further demonstrate that endogenous latent TGF-0 can be activated and suppress both CTL generation in vitro and NK activity in vivo.
A key towards understanding the target specificity ofTGF-0 action is elucidation of the processes by which latent TGF-0 becomes biologically active . Recent studies have suggested that activated macrophages have the potential to both secrete and activate latent TGF-0, although the mechanisms involved in this conversion are not known . Acidic conditions can convert latent TGF-0 to active (11) , suggesting that acidic cellular environments may provide a physiologic milieu in which activation may occur (44, 45) . From microelectrode studies it has been shown that macrophages, as well as osteoclasts, contain such acidic microenvironrnents (46) that may be sufficiently low to activate TGF-f3 . Moreover, the observation that activated macrophages express sialidase activity (47) , coupled with the finding that removal of sialic-acid-containing carbohydrate structures in the TGF-0 precursor remnant can activate TGF-0 (14), further substantiates the possible role of the macrophage as an activator of latent TGF-/3 . We have found that LPS-stimulated human peripheral blood-derived adherent macrophages did not significantly activate exogenously added purified latent TGF-,B 1 (data not shown) . This result does not preclude the possibility that antigenpresenting macrophages can activate latent TGF-(3, but may indicate the need for cognate help by other cell types during activation . In support of this hypothesis, Antonelli-Orlidge et al. report that the conditioned media of endothelial cells and pericytes each contained latent TGF-(3, but only during their co-culture can activated TGF-0 be produced (48) . At the current time we have no information to support or exclude the possibility that CHO or CHO-TGF-01 cells themselves can activate latent TGF-/3. Our results showing that activation of latent TGF-0 occurs during the generation of immune cytolytic cells may indicate that de novo induction of lymphoid maturation proteins or cell surface differentiation markers are pre-requisites for TGF-0 activation .
Once activated, TGF -R1 displays potent immunosuppression in vivo of NK cytolytic activity, the ability of splenocytes to respond to mitogenic stimuli, and CTL generation in vitro, which are shown in this report and previously (26-28). As suggested by Rook et al., TGF-0 may affect the continuous recruitment and activation of "pre-NK" cells by blunting their ability to respond to IFN-a, an important growth factor for NK activation and function (26). The blunting of IFN-a responsiveness may reflect downregulation of IFN-ci receptor numbers expressed on NK cells by TGF-0 . In addition, TGF-0 may affect the differentiation oflymphoid cells as shown for Ig-secreting B cells (21, 22), CTLs (27) , and LAK cells (30) , possibly by lowering lymphocyte cell receptors for 11,2 (20). Alternatively, TGF-(3 may inhibit the generation of CTLs, and also LAK cells, by dampening TNF-ci production (25), an important modulator ofboth CTL and LAK cell development (27, 30) . Interestingly, TGF-0 does not effect the ability of either lymphoid cells (27) or tumor cells (data presented here) to serve as targets for lysis by mature CTLs. This finding suggests that TGF-N1 might not affect MHC class I expression on CHO cells, in contrast to its ability to modulate class II HLADR surface antigen expression on human cells (34, 35) .
Within the framework of the complex immune cell network, TGF-0 is also shown to downregulate both NK activity and primary CTL responses in vivo (49) . Tumor cells that produce TGF-0 may therefore potentially reduce the numbers or generation of circulating rytolytic CTL and NK cells and thus promote escape of the tumor from immune surveillance. Clinically, patients with glioblastomas, which secrete TGF-/32 (50) , demonstrate a generalized immune suppression; manifested especially by an inability of normal T cells to respond to mitogens (51) . Moreover, TGF-J3-producing tumors can grow progressively in transiently immunosuppressed mice while retaining expression for class I MHC (49) . Thus, TGF-0 by inhibition of host immune responses may provide a mechanism to suppress allograft rejection and may possibly accelerate processes of carcinogenesis.
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